Search Results - "Beaumont, Donna M."

The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer by Inglis, Daniel J, Lavranos, Tina C, Beaumont, Donna M, Leske, Annabell F, Brown, Chloe K, Hall, Allison J, Kremmidiotis, Gabriel

“…BNC105 is a tubulin targeting compound that selectively disrupts vasculature within solid tumors. The severe tumor hypoxia and necrosis that ensues translates…”
Get full text

Abstract 4695: Targeting the LGR5 complex with BNC101 to improve checkpoint inhibitor therapy in colorectal cancer by Inglis, Daniel J., Beaumont, Donna M., Lavranos, Tina C.

“…LGR5 is a well characterised marker of intestinal stem cells found at the base of intestinal crypts and a receptor for R-spondins, potent Wnt signalling…”
Get full text

Abstract 4982: BNC105 induces tumor micro-environment changes which enhance the efficacy of checkpoint inhibitor therapy in preclinical models by Inglis, Daniel J., Beaumont, Donna M., Leske, Annabell F., Scherer, Michaela A., Lavranos, Tina C.

“…BNC105 is a Phase II stage drug that specifically targets tubulin causing rapid depolymerisation. The therapeutic window of BNC105 has been shown to be…”
Get full text

Abstract 3910: Characterization of BNC101 a human specific monoclonal antibody targeting the GPCR LGR5: First-in-human evidence of target engagement by Inglis, Daniel J., Licari, John, Georgiou, Kristen R., Wittwer, Nicole L., Hamilton, Ross W., Beaumont, Donna M., Scherer, Michaela A., Lavranos, Tina C.

“…At the base of normal intestinal crypts, stem cells maintain the highly regenerative gut epithelium. These intestinal stem cells are well characterized for…”
Get full text

Abstract 1881: The microtubule-disrupting drug BNC105 is a potent inducer of apoptosis in AML patient samples by Inglis, Daniel J., Casolari, Debora A., Nguyen, Tran, Beaumont, Donna M., Wittwer, Nicole L., Ross, David, D'Andrea, Richard, Lavranos, Tina C.

“…BNC105 is a phase II potent and highly selective disruptor of tumor microvasculature that causes the rapid onset of hypoxia and necrosis in solid tumors…”
Get full text

Abstract B67: Induction of tumor hypoxia synergises with inhibitors of tumor metabolic and angiogenic adaptive responses to suppress tumor growth and enhance host survival by Inglis, Daniel J., Lavranos, Tina C., Beaumont, Donna M., Leske, Annabell F., Brown, Chloe K., Kremmidiotis, Gabriel

“…BNC105 is a compound that exerts an anti-cancer action through selective destruction of tumor blood vessels. A single IV dose of BNC105 causes a very high…”
Get full text

Abstract 4039: Harnessing the tumor adaptive response to hypoxia to identify novel combinations of the vascular disrupting agent BNC105 with targeted therapeutics by Lavranos, Tina C., Inglis, Daniel J., Beaumont, Donna M., Leske, Annabell F., Brown, Chloe K., Kremmidiotis, Gabriel

“…BNC105 is a small molecule Vascular Disrupting Agent (VDA) that exerts anti-cancer activity through selective shut-down of tumor blood vessels. A single dose…”
Get full text

Abstract 3543: Anti-tumor activity of the vascular disruption agent BNC105 in models of mesothelioma and lung cancer by Leske, Annabell F., Beaumont, Donna M., Lavranos, Tina C., Gasic, Jelena, Kremmidiotis, Gabriel

“…BNC105 is a small molecule that exerts anti-cancer activity through disruption of tubulin polymerisation. BNC105 is unique in its ability to selectively target…”
Get full text

Abstract 662: Evaluation of the anti-cancer effects of the tumor selective vascular disruption agent BNC105 in preclinical renal cancer models by Lavranos, Tina C., Leske, Annabell F., Beaumont, Donna M., Gasic, Jelena, Kremmidiotis, Gabriel

“…The disruption of blood vessels that feed tumors represents one of the most promising therapeutic strategies for treating cancer. BNC105 is a tubulin targeting…”
Get full text

Abstract 2498: BNC105 is a tubulin polymerization inhibitor that exhibits vascular disruptive activity in renal cancer and causes upregulation in HIF1alpha, HIF2alpha and mTOR by Leske, Annabell F., Beaumont, Donna M., Lavranos, Tina C., Gasic, Jelena, Coles, Carolyn J., Matthews, Clayton A., Phillips, Renee J., Kremmidiotis, Gabriel

“…BNC105 is a tubulin polymerization inhibitor. This agent selectively disrupts the vasculature in tumors, and in addition acts as a direct cytotoxic against…”
Get full text